Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo (Sanofi) covers the month of March 2003 and includes the consolidated financial statements for the fiscal year ended December 31, 2002. The company is a French pharmaceutical firm headquartered in Paris. The filing also announces a regulatory milestone for its product ARIXTRA (fondaparinux sodium) in the United States.
Key Financial Metrics (Year Ended Dec 31, 2002)
- Revenue: Net sales totaled €7,448 million.
- Profitability: Net income was €1,759 million, with earnings per share (basic and diluted) of €2.42. Operating profit was €2,614 million.
- Margins: Gross profit margin was approximately 81.5% (€6,070 million gross profit on €7,448 million sales). Operating margin was approximately 35.1%.
- Cash Flow: Net cash provided by operating activities was €1,676 million. Net cash used in investing activities was €1,409 million, and net cash used in financing activities was €1,591 million.
- Liquidity: Cash and cash equivalents at year-end were €2,465 million. Short-term investments and deposits were €2,944 million.
- Debt: Total debt consisted of €65 million in long-term debt and €351 million in short-term debt.
- Balance Sheet: Total assets were €9,459 million, and total shareholders' equity was €6,035 million.
Material Changes Versus Prior Period
- Revenue Growth: Net sales increased 14.8% from €6,488 million in 2001 to €7,448 million in 2002.
- Profit Growth: Net income rose 11.0% from €1,585 million in 2001 to €1,759 million in 2002. Operating profit increased 24.1% to €2,614 million.
- Expense Trends: Research and development expenses increased 18.1% to €1,218 million. Selling and general expenses rose 5.3% to €2,428 million.
- Investing Activity: Capital expenditures and acquisitions surged significantly, with total investments rising from €619 million in 2001 to €1,435 million in 2002.
- Shareholder Returns: Dividends paid to shareholders increased from €317 million in 2001 to €473 million in 2002. The company also repurchased shares totaling €963 million in 2002.
- Cash Position: Despite strong operating cash flow, the net change in cash and cash equivalents was a decrease of €1,340 million, driven by heavy investing and financing outflows.
Guidance, Outlook, and Material Events
- Regulatory Approval: The U.S. FDA granted a six-month priority review for ARIXTRA for a new indication: extended prophylaxis of deep venous thrombosis in patients undergoing hip fracture surgery. The application was submitted on December 17, 2002.
- Product Profile: ARIXTRA is a synthetic antithrombotic agent co-developed with Organon. It is currently indicated for prophylaxis in hip fracture, hip replacement, and knee replacement surgeries. Extended prophylaxis may involve up to an additional 24 days of administration.
- Risks and Contingencies: The filing notes risks associated with bleeding, particularly in patients with impaired kidney function, low body weight, or advanced age. A boxed warning exists regarding spinal/epidural hematomas. Forward-looking statements highlight risks related to U.S. market expansion, R&D success, intellectual property protection, and healthcare reimbursement/pricing reforms in the U.S. and France.
- Management Commentary: Management expects to establish a strong position in the antithrombotic field with ARIXTRA and is conducting further clinical investigations for other indications including acute coronary syndrome.
Key Facts for Investor Verification
- Verify the outcome of the FDA priority review for ARIXTRA's extended prophylaxis indication.
- Confirm the sustainability of the 14.8% revenue growth rate in the context of global pharmaceutical pricing pressures.
- Assess the impact of the €1.4 billion increase in capital expenditures and acquisitions on future cash flow and debt levels.
- Monitor the execution of the €963 million share repurchase program and its effect on earnings per share.
- Review the specific details of the "Change in accounting method" noted in the shareholders' equity statement, which added €24 million to reserves.